ReviewJournal of Parkinson's disease2022
Neuroinflammation and Immune Changes in Prodromal Parkinson's Disease and Other Synucleinopathies.
Review in Journal of Parkinson's disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 64 citations in OpenAlex.
- Integrating retinal and brain imaging biomarkers for diagnosis of parkinson's disease: findings from a time-lagged cross-sectional persian cohort study.Scientific reports · 2026Article
- When neuroprotection fails early: prokineticin downregulation in idiopathic REM sleep behavior disorder.Sleep · 2026Article
- Article
- Navigating the Ethereal Tightrope: The Nanogenerator Manipulates Neurons for Immune Equilibrium.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Manifestations of different sleep disorders in patients with vascular parkinsonism and their impact on prognosis.American journal of translational research · 2026Article
- Depending on intensity, exercise improved or worsened pathology in a model of prodromal Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Modified Mediterranean diet effects on Parkinson's disease (MED-PARK): a single-centre randomised controlled trial protocol.BMJ open · 2025Article
- Neuroinflammatory Mechanisms and Vocalization Biomarkers in theMedical research archives · 2025Article
- Whole transcriptome analysis of peripheral blood mononuclear cells from de novo and drug-naive Parkinson's disease patients.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Article
- Lung function and the risk of Parkinson's disease: a population-based cohort study.Journal of neurology · 2025Article
- Aerobic exercise-induced changes in fluid biomarkers in Parkinson's disease.NPJ Parkinson's disease · 2025Review
- Microbiota-neuroepithelial signalling across the gut-brain axis.Nature reviews. Microbiology · 2025Review
- T cell responses towards PINK1 and α-synuclein are elevated in prodromal Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Microglial dynamics and neuroinflammation in prodromal and early Parkinson's disease.Journal of neuroinflammation · 2025Review
- Gastrointestinal Dysfunction Bears on the Clinical-Biological Profile of Parkinson's Disease.Movement disorders clinical practice · 2025Article
- The immune system in Parkinson's disease: what we know so far.Brain : a journal of neurology · 2024Review
- Multiomics of parkinsonism cynomolgus monkeys highlights significance of metabolites in interaction between host and microbiota.NPJ biofilms and microbiomes · 2024Article
- PARK7/DJ-1 deficiency impairs microglial activation in response to LPS-induced inflammation.Journal of neuroinflammation · 2024Article
- Experimental Models to Study Immune Dysfunction in the Pathogenesis of Parkinson's Disease.International journal of molecular sciences · 2024Review
- Amyloid-β aggregates activate peripheral monocytes in mild cognitive impairment.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple lines of clinical and pre-clinical research support a pathogenic role for neuroinflammation and peripheral immune system dysfunction in Parkinson's disease. In this paper, we have reviewed and summarised the published literature reporting evidence of neuroinflammation and peripheral immune changes in cohorts of patients with isolated REM sleep behaviour disorder and non-manifesting carriers of GBA or LRRK2 gene mutations, who have increased risk for Parkinsonism and synucleinopathies, and could be in the prodromal stage of these conditions. Taken together, the findings of these studies suggest that the early stages of pathology in Parkinsonism involve activation of both the central and peripheral immune systems with significant crosstalk. We consider these findings with respect to those found in patients with clinical Parkinson's disease and discuss their possible pathological roles. Moreover, those factors possibly associated with the immune response, such as the immunomodulatory role of the affected neurotransmitters and the changes in the gut-brain axis, are also considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.